Bolazine caproate is an injectable anabolic steroid derived from dihydrotestosterone. This agent is a close chemical cousin of dimethazine, which is also known as mebolazine (for methyl bolazine). Bolazine is a unique steroid that is made from two molecules of drostanolone bonded together. This bond is broken once in the body, however, so this drug ultimately provides the same active drostanolone as Masteron. Bolazine is a strong anabolic agent with moderate androgenicity and no estrogenic or progestational properties. This drug, although no longer produced, was once highly favored by athletes for its ability to promote solid muscle tissue gains without unnecessary water or fat retention. The results from bolazine are qualitatively identical to those of Masteron, and for all intents and purposes the two agents are interchangeable.
|Brand name||Roxilon Inject, Bolazine caproate|
|Progestational Activity||no data available (low)|
Roxilon Inject History
Bolazine caproate first appeared in Europe in the 1960's. It was developed into a medicine by Ormonoterapia Richter in Milan, Italy, which sold it under the brand name Roxilon Inject. As the name implies, the drug was intended to be an injectable (non-alkylated) version of the firm's oral Roxilon medication (dimethazine; mebolazine). Although c-17 methylated and non-methylated analogs often tend to have very different activities from one another, here the separation between the two agents is not great, and therefore the comparison is somewhat appropriate. Owing to their high relative anabolic to androgenic ratios, Roxilon and Roxilon Inject were both used clinically to treat a variety of androgen-sensitive populations, including women, the elderly, and children. Although clinically effective, both steroids saw limited financial success, and Richter discontinued them many years ago. There is currently no legitimate prescription drug product worldwide containing bolazine caproate.
How is Roxilon Inject Supplied
Bolazine caproate is no longer available as a prescription drug preparation.
Structural Characteristics of Roxilon Inject
Drostanolone is a modified form of dihydrotestosterone. It differs by the introduction of a methyl group at carbon-2 (alpha), which considerably increases the anabolic strength of the steroid by heightening its resistance to metabolism by the 3-hydroxysteroid dehydrogenase enzyme in skeletal muscle tissue. Bolazine consists of two drostanolone molecules bonded together with an azine bridge. These molecules are metabolically separated, yielding free drostanolone. Bolazine caproate is a modified form of bolazine, where a carboxylic acid ester (caproic acid) has been attached to the 17-beta hydroxyl group to slow its release from the site of injection (depot).
Roxilon Inject Side Effects (Estrogenic)
Bolazine is not aromatized by the body, and is not measurably estrogenic. An anti-estrogen is not necessary when using this steroid, as gynecomastia should not be a concern even among sensitive individuals. Since estrogen is the usual culprit with water retention, this steroid instead produces a lean, quality look to the physique with no fear of excess subcutaneous fluid retention. This makes it a favorable steroid to use during cutting cycles, when water and fat retention are major concerns. As a non-aromatizable DHT derivative, this steroid may also impart an anti-estrogenic effect, the drug competing with other (aromatizable) substrates for binding to the aromatase enzyme.
Roxilon Inject Side Effects (Androgenic)
Although classified as an anabolic steroid, androgenic side effects are still possible with this substance, especially with higher doses. This may include bouts of oily skin, acne, and body/facial hair growth. Anabolic/androgenic steroids may also aggravate male pattern hair loss. Women are warned of the potential virilizing effects of anabolic/androgenic steroids. These may include a deepening of the voice, menstrual irregularities, changes in skin texture, facial hair growth, and clitoral enlargement. Bolazine is a steroid with relatively low androgenic activity relative to its tissue-building actions, making the threshold for strong androgenic side effects comparably higher than with more androgenic agents such as testosterone, methandrostenolone, or fluoxymesterone. Note that bolazine is unaffected by the 5-alpha reductase enzyme, so its relative androgenicity is not affected by the concurrent use of finasteride or dutasteride.
Roxilon Inject Side Effects (Heoatotoxicity)
Bolazine is not cl 7-alpha alkylated, and not known to have hepatotoxic properties. Liver toxicity is unlikely.
Roxilon Inject Side Effects (Cardiovascular)
Anabolic/androgenic steroids can have deleterious effects on serum cholesterol. This includes a tendency to reduce HDL (good) cholesterol values and increase LDL (bad) cholesterol values, which may shift the HDL to LDL balance in a direction that favors greater riskof arteriosclerosis. The relative impact of an anabolic/androgenic steroid on serum lipids is dependant on the dose, route of administration (oral vs. injectable), type of steroid (aromatizable or non-aromatizable), and level of resistance to hepatic metabolism. Bolazine should have a stronger negative effect on the hepatic management of cholesterol than testosterone or, nandrolone due to its non-aromatizable nature, but a weaker impact than c-17 alpha alkylated steroids. Anabolic/androgenic steroids may also adversely affect blood pressure and triglycerides, reduce endothelial relaxation, and support left ventricular hypertrophy, all potentially increasing the risk of cardiovascular disease and myocardial infarction.
To help reduce cardiovascular strain it is advised to maintain an active cardiovascular exercise program and minimize the intake of saturated fats, cholesterol, and simple carbohydrates at all times during active AAS administration. Supplementing with fish oils (4 grams per day) and a natural cholesterol/antioxidant formula such as Lipid Stabil or a product with comparable ingredients is also recommended.
Roxilon Inject Side Effects (Testosterone Suppression)
All anabolic/androgenic steroids when taken in doses sufficient to promote muscle gain are expected to suppress endogenous testosterone production. Without the intervention of testosterone-stimulating substances, testosterone levels should return to normal within 1-4 months of drug secession. Note that prolonged hypogonadotrophic hypogonadism can develop secondary to steroid abuse, necessitating medical intervention.
Roxilon Inject Administration (Men)
An effective dose for physique- or performanceenhancing purposes falls in the range of 150-400 mg per week, taken for 6-12 weeks. This level is sufficient to provide measurable gains in lean muscle mass and strength, which (depending on diet and metabolic factors) may be accompanied by increased hardness and definition to the physique. Due to the slow-acting nature of this drug, injections are typically given once per week.
Roxilon Inject Administration (Women)
When used for physique- or performance-enhancing purposes, a dosage of 50-100 mg per week is most common,taken for 4 to 6 weeks. Virilization symptoms are rare in doses of 100 mg per week or below. This level is sufficient to provide measurable gains in lean muscle mass and strength, which (depending on diet and metabolic factors) may be accompanied by increased hardness and definition to the physique.
Roxilon Inject Availability
Bolazine caproate is no longer available as a prescription drug product.
Wlliam Llewellyn (2017) - Anabolics